Skip to main content

Allscripts Healthcare Solution Value Stock - Dividend - Research Selection

Allscripts healthcare solution

ISIN: US01988P1084 , WKN: 607917

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Allscripts Healthcare Solutions, Inc. provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions. The company\'s Clinical and Financial Solutions segment provides integrated clinical software applications and financial and information solutions, which primarily include EHR-related, and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training, and electronic claims administration services. Its Population Health segment offers health management and coordinated care solutions that enable hospitals, health systems, accountable care organizations, and other care facilities to connect, transition, analyze, and coordinate care across the entire care community. The company\'s Netsmart segment operates in and provides software and technology solutions to the health and human services, and post-acute sectors of health care. The company serves physicians, hospitals, governments, health systems, health plans, life-sciences companies, retail clinics, retail pharmacies, pharmacy benefit managers, insurance companies, and employer wellness clinics, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Veradigm Payerpath Rated Highest in Client Satisfaction

2024-05-30
CHICAGO, May 30, 2024--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book Research, a healthcare-centric market research and public opinion research and consulting company, rated Veradigm Payerpath the overall number one provider of claims and clearinghouse platform solutions for small medical practices.

Veradigm to Explore Strategic Alternatives and Reaffirms 2024 Guidance

2024-05-28
CHICAGO, May 28, 2024--Veradigm Inc. (OTCMKTS: MDRX, the "Company"), a leading provider of healthcare data and technology solutions, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value.

Veradigm Announces Leadership Updates

2024-05-28
CHICAGO, May 28, 2024--Veradigm Inc. (OTCMKTS: MDRX, the "Company"), a leading provider of healthcare data and technology solutions, today announced that, on June 7, 2024, Tom Langan, the Company’s President and Chief Commercial Officer (CCO), will assume the role of interim Chief Executive Officer (CEO), reporting directly to the Executive Chairman and the Board. Mr. Langan has been a Company leader since 2018 and has more than 25 years of life sciences, payer and data & analytics experience. I

Veradigm Explores Strategic Options, Reaffirms 2024 Outlook

2024-05-28
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Veradigm names new interim CEO, reaffirms guidance, explores strategic alternatives

2024-05-28
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Veradigm price target lowered by $11 at TD Cowen, here's why

2024-05-28
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Veradigm backs FY24 revenue view $620M-$635M, consensus $630.71M

2024-05-28
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Veradigm initiates process to explore strategic alternatives

2024-05-28
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Veradigm interim CEO Yin Ho to step down, CCO Tom Langan to assume role

2024-05-28
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Buy Rating Affirmed for Veradigm: Growth Prospects and Market Position Highlighted

2024-05-28
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.